Chimeric Immunomodulatory Compounds Shifting Immune Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapies often induce Th2-type immune responses, which are ineffective against viral infections and intracellular pathogens, and can lead to allergic reactions, highlighting a need for compounds that can modulate the immune response to promote Th1-type responses.
Innovation Solution
Development of chimeric immunomodulatory compounds (CICs) comprising nucleic acid and non-nucleic acid moieties, specifically designed to stimulate IFN-γ production and B cell proliferation, with core structures that include nucleic acid moieties like 5′-TCG-3′ sequences covalently joined with non-nucleic acid spacer moieties such as triethylene glycol or dendrimers, to enhance immune modulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If protein-based vaccines are used to induce immune response, then antibody production is improved, but cell-mediated immunity is insufficient and allergic reactions may occur
Solution Approach 1:
The patent changes the molecular parameters of the immunomodulator by incorporating specific nucleic acid sequences (CG dinucleotides, TCGA tetranucleotides) and modifying their chemical structure (phosphorothioate linkages, 2'-fluoro modifications) to shift the immune response from Th2-dominated (antibody-based) to Th1-dominated (cell-mediated) phenotype, thereby improving cell-mediated immunity while maintaining antibody production
Solution Approach 2:
The patent creates chimeric molecules combining nucleic acid moieties with non-nucleic acid spacers (such as dendrimers, polymers, or small molecules) to form composite immunomodulatory compounds that simultaneously enhance both antibody production and cell-mediated immunity by engaging multiple immune pathways
2Quantity of substance
If Th2-type immune response is induced, then antibody response is enhanced, but protection against viral infections and intracellular pathogens is reduced
Solution Approach 1:
The patent modifies the immune response parameters by using nucleic acid sequences with specific base compositions (CG-rich, TCGA-containing) that are recognized by TLR9 and other pattern recognition receptors, thereby shifting the cytokine profile from Th2 (IL-4, IL-5, IL-13) to Th1 (IFN-γ, IL-2, TNF-α), which provides effective protection against viral and intracellular pathogens
3Reliability
If conventional immunomodulatory polynucleotides are used, then Th1-type response is improved, but the compounds lack versatility and specificity for different disease indications
Solution Approach 1:
The patent divides the immunomodulatory compound into modular components: nucleic acid moieties containing immunostimulatory sequences (such as TCGA tetranucleotides or CG dinucleotides) and non-nucleic acid spacer moieties (dendrimers, polymers, small molecules). This segmentation allows independent optimization of each component for different disease indications while maintaining overall Th1-type response activation
Solution Approach 2:
The patent creates universal immunomodulatory platforms where the same nucleic acid sequences (e.g., TCGA tetranucleotides) can be combined with different spacer moieties to address multiple disease indications including viral infections, cancer, autoimmunity, and allergic diseases, thereby achieving both reliability of Th1 response and versatility across indications
Data Source
AI summary
The invention provides immunomodulatory compounds and methods for immunomodulation of individuals using the immunomodulatory compounds.